Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders

Moli Fan, MD, PhD,* Wei Qiu, MD, PhD,* Bitao Bu, MD, PhD,* Yan Xu, MD, PhD,* Huan Yang, MD, Dehui Huang, MD, Alexander Y. Lau, MD, Jun Guo, MD, PhD, Mei-Ni Zhang, MD, Xinghu Zhang, MD, PhD, Chun-Sheng Yang, MD, PhD, Jingshan Chen, MD, Pei Zheng, MD, Qiang Liu, MD, PhD, Chao Zhang, MD, PhD, and Fu-Dong Shi, MD, PhD


Abstract

Objective
Disease-modifying drugs (DMDs) may alter the immune status and thus increase the susceptibility to coronavirus disease 2019 (COVID-19) in patients with MS or neuromyelitis optica spectrum disorders (NMOSD). However, evidence supporting this notion is currently lacking. In this study, we conducted a survey on the risk of COVID-19 in patients with MS and NMOSD.

Methods
The survey was conducted through the Chinese Medical Network for Neuroinflammation. Patients in 10 MS centers from 8 cities including Wuhan were included. Information about MS and NMOSD disease duration and the usage of DMDs were collected. Data of suspected cases of COVID-19 were obtained from hospital visits, questionnaires, and patient self-reporting. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was confirmed through clinical evaluation by a panel of experts in conjunction with chest CT and viral RNA detection.

Results
Eight hundred eighty-two of 1,804 (48.89%) patients with MS and 2,129 of 3,060 (69.58%) patients with NMOSD were receiving DMDs. There were no alterations in the patients’ DMD regimen during January 15, 2020, to March 15, 2020, the 3-month period. None of the patients with MS treated with DMDs had COVID-19. However, 2 patients with relapsing NMOSD were diagnosed with COVID-19-related pneumonia. After treatment, both patients recovered from pneumonia and neither patient experienced new attacks due to predisposing SARS-CoV-2 infection in the following 2 months.

Conclusions
No increased risk of COVID-19 infection was observed in patients with MS or NMOSD, irrespective of whether these patients received DMDs. A battery of stringent preventive measures adopted by neurologists to reduce COVID-19 infection in these patients may have contributed to low risk of COVID-19 infection.
The number of the novel coronavirus disease 2019 (COVID-19) cases and mortality grow rapidly around the world. Aged individuals with preexisting medical conditions are at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with disease and mortality occurring predominantly in this group.\(^1\)–\(^3\) It is thus conceivable that patients with MS or neuromyelitis optica spectrum disorders (NMOSDs) who are receiving disease-modifying treatments have increased susceptibility to COVID-19 infection and disease. However, evidence supporting this notion is currently lacking.

**Methods**

We have conducted a survey through the Chinese Medical Network for Neuroinflammation (CMNN). The CMNN consists of neurologists specialized in managing patients with MS and NMOSD from 47 hospitals across China (figure 1). MS and NMOSD were diagnosed according to the 2017 McDonald criteria and 2015 International Panel for Neuromyelitis Optica Diagnosis criteria, respectively. All patients with MS and NMOSD managed in 10 centers from 8 cities including Wuhan were enrolled in this study. Information about disease duration and usage of disease-modifying drugs (DMDs) were collected. Data of suspected cases of COVID-19 were obtained from hospital visits, online questionnaires (supplementary file, links.lww.com/NXI/A266), and patient self-reporting via emails or phone calls. Patients who did not respond to questionnaires were excluded from this study. Confirmation of SARS-CoV-2 infection was determined through clinical evaluation by a panel of experts in conjunction with a set of tests including chest CT and viral RNA detection by real-time fluorescent PCR from nasopharyngeal swab samples.

**Data availability**

All data are published in this article.

**Results**

We conducted a survey for COVID-19 infection during January 15 to March 15. One thousand eight hundred four of
1,836 (98.26%) patients with MS and 3,060 of 3,128 (97.82%) patients with NMOSD from 10 MS/NMOSD centers across China, including Tongji Hospital from Wuhan, have responded (figure 2). The mean disease duration was 4.64 years for patients with MS and 4.94 years for patients with NMOSD. For MS, 882 (48.89%) patients were receiving DMDs, and the remaining patients received non-DMDs such as corticosteroids, traditional Chinese medicines, or other drugs. For NMOSD, 2,129 (69.58%) patients were receiving DMDs. There were no alterations in the patients’ DMD regimen during this 3-month period (table, figures 3 and 4). None of the patients with MS treated with DMDs were diagnosed with COVID-19. However, 2 patients with relapsing NMOSD, a 53-year-old man from Wuhan and a 49-year-old man from Beijing, were diagnosed with COVID-19-related pneumonia, and SARS-CoV-2 infection was confirmed by viral RNA detection. Both patients had received oral methylprednisolone as maintenance therapy to prevent relapses, and neither had been treated with other DMDs after diagnosis. After treatment according to the Chinese protocols for COVID-19, both patients recovered from pneumonia and neither had been treated with other DMDs after diagnosis. Neurologists from centers who have not contributed to these data have reported no COVID-19-infected patients with MS or NMOSD diagnosed in their clinic.

Discussion

Natalizumab, rituximab, and fingolimod usage is associated with reactivation of John Cunningham virus and progressive multifocal leukoencephalopathy in patients with MS. Side effects for newer therapies such as eculizumab, inebilizumab, satralizumab, and tocilizumab in NMOSD are unclear, partly because of the relatively short duration and small numbers of patients’ exposure to these medications. Because these DMDs interfere with multiple arms of the immune system, altered immune functions in these patients are expected. Despite this anticipated risk, we did not observe an escalated rate of COVID-19 infection, even at the epicenter of the outbreak in Wuhan. SARS-CoV-2 has spread to all the provinces of China from the Wuhan epicenter since January 2020. The overall incidence of COVID-19 infection in China is estimated at 6/10^5 subjects comparable with the estimated incidence of NMOSD in China. These results from China are consistent with observations in some MS centers from Korea, Japan, and Singapore where no COVID-19 cases have been reported for patients with MS or NMOSD treated with DMDs (personal communications). As with the general public, patients with MS and NMOSD do not have immunity to SARS-CoV-2, and altered immunity induced by DMDs in patients with MS or NMOSD, if any, appears insufficient to enhance the susceptibility to infection.

Figure 2 Distribution map of COVID-19 cases across China and cities and hospitals surveyed (red) for this study

Cumulative number of confirmed COVID-19 infections

- >1,000
- 1,000–10,000
- 500–999
- 100–499
- <100

Cumulative number of confirmed COVID-infections for hospitals surveyed / population in each city

- Wuhan: 50,004/14.2 million
- Beijing: 456/21.5 million
- Guangzhou: 351/14.9 million
- Changsha: 242/8.2 million
- Hong Kong: 162/7.5 million
- Tianjin: 136/15.6 million
- Xian: 120/10.0 million
- Taiyuan: 20/4.2 million

Table  DMDs used by MS and NMOSD patients and confirmed COVID-19 cases in 10 centers from 8 cities in China

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Cities of MS/NMOSD centers surveyed</th>
<th>Wuhan</th>
<th>Beijing</th>
<th>Guangzhou</th>
<th>Changsha</th>
<th>Hong Kong</th>
<th>Tianjin</th>
<th>Xi’an</th>
<th>Taiyuan</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population (million)</td>
<td></td>
<td>14.2</td>
<td>21.5</td>
<td>14.9</td>
<td>8.2</td>
<td>7.5</td>
<td>15.6</td>
<td>10.0</td>
<td>4.2</td>
<td>96.1</td>
</tr>
<tr>
<td>COVID-19 confirmed</td>
<td></td>
<td>50,004</td>
<td>456</td>
<td>351</td>
<td>242</td>
<td>162</td>
<td>136</td>
<td>120</td>
<td>20</td>
<td>51,491</td>
</tr>
<tr>
<td>No. of patients with MS</td>
<td></td>
<td>78</td>
<td>796</td>
<td>350</td>
<td>152</td>
<td>160</td>
<td>90</td>
<td>34</td>
<td>144</td>
<td>1804</td>
</tr>
<tr>
<td>Disease duration, mean, y</td>
<td></td>
<td>6.63</td>
<td>1.9</td>
<td>4.55</td>
<td>11.45</td>
<td>4.61</td>
<td>5.96</td>
<td>5.2</td>
<td>4.64</td>
<td></td>
</tr>
<tr>
<td>DMDs, n (%)</td>
<td></td>
<td>51 (65.40)</td>
<td>324 (42.13)</td>
<td>146 (41.71)</td>
<td>56 (36.84)</td>
<td>138 (62.22)</td>
<td>56 (62.22)</td>
<td>27 (79.41)</td>
<td>84 (58.33)</td>
<td>882 (48.89)</td>
</tr>
<tr>
<td>Interferon beta</td>
<td></td>
<td>9 (11.50)</td>
<td>51 (6.63)</td>
<td>5 (1.43)</td>
<td>14 (9.21)</td>
<td>34 (21.26)</td>
<td>0</td>
<td>1 (2.94)</td>
<td>45 (31.25)</td>
<td>159 (8.81)</td>
</tr>
<tr>
<td>Teriflunomide</td>
<td></td>
<td>30 (38.50)</td>
<td>226 (29.39)</td>
<td>91 (26.00)</td>
<td>42 (27.63)</td>
<td>20 (12.50)</td>
<td>30 (33.33)</td>
<td>9 (26.47)</td>
<td>27 (18.75)</td>
<td>475 (26.33)</td>
</tr>
<tr>
<td>Fingolimod</td>
<td></td>
<td>0</td>
<td>27 (3.51)</td>
<td>2 (0.57)</td>
<td>0</td>
<td>31 (19.38)</td>
<td>1 (1.25)</td>
<td>2 (5.88)</td>
<td>0</td>
<td>63 (3.49)</td>
</tr>
<tr>
<td>Rituximab</td>
<td></td>
<td>6 (7.70)</td>
<td>12 (1.56)</td>
<td>34 (9.71)</td>
<td>0</td>
<td>4 (2.50)</td>
<td>25 (31.25)</td>
<td>15 (44.12)</td>
<td>12 (8.33)</td>
<td>108 (5.99)</td>
</tr>
<tr>
<td>Dimethyl fumarate</td>
<td></td>
<td>0</td>
<td>1 (0.13)</td>
<td>6 (1.71)</td>
<td>0</td>
<td>39 (24.38)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>46 (2.55)</td>
</tr>
<tr>
<td>Cladribine</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6 (3.75)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6 (0.33)</td>
<td></td>
</tr>
<tr>
<td>Alemtuzumab</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4 (2.50)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4 (0.22)</td>
</tr>
<tr>
<td>COVID-19 confirmed</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>No. of patients with NMOSD</td>
<td></td>
<td>588</td>
<td>1,079</td>
<td>450</td>
<td>453</td>
<td>30</td>
<td>155</td>
<td>158</td>
<td>147</td>
<td>3,060</td>
</tr>
<tr>
<td>Disease duration, mean, y</td>
<td></td>
<td>5.87</td>
<td>3.8</td>
<td>3.75</td>
<td>12.69</td>
<td>5.52</td>
<td>5.5</td>
<td>7.2</td>
<td>4.94</td>
<td></td>
</tr>
<tr>
<td>DMDs, n (%)</td>
<td></td>
<td>420 (71.43)</td>
<td>697 (64.6)</td>
<td>375 (83.33)</td>
<td>268 (59.16)</td>
<td>22 (73.33)</td>
<td>113 (24.94)</td>
<td>55 (35.48)</td>
<td>8 (5.06)</td>
<td>795 (25.98)</td>
</tr>
<tr>
<td>Methylprednisolone*</td>
<td></td>
<td>36 (6.12)</td>
<td>30 (2.78)</td>
<td>412 (91.56)</td>
<td>113 (24.94)</td>
<td>4 (1.23)</td>
<td>55 (35.48)</td>
<td>8 (5.06)</td>
<td>137 (93.20)</td>
<td>97 (65.99)</td>
</tr>
<tr>
<td>Azathioprine*</td>
<td></td>
<td>18 (3.06)</td>
<td>104 (9.64)</td>
<td>180 (40.00)</td>
<td>65 (14.40)</td>
<td>12 (2.9)</td>
<td>7 (4.43)</td>
<td>2 (1.29)</td>
<td>17 (11.56)</td>
<td>405 (13.24)</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td></td>
<td>24 (4.08)</td>
<td>439 (40.69)</td>
<td>146 (32.44)</td>
<td>173 (38.15)</td>
<td>6 (2.00)</td>
<td>6 (3.87)</td>
<td>6 (3.80)</td>
<td>32 (21.77)</td>
<td>832 (27.19)</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td></td>
<td>360 (61.22)</td>
<td>17 (1.58)</td>
<td>14 (3.11)</td>
<td>12 (2.60)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>403 (13.17)</td>
</tr>
<tr>
<td>Rituximab</td>
<td></td>
<td>12 (2.04)</td>
<td>93 (8.62)</td>
<td>29 (6.44)</td>
<td>18 (3.94)</td>
<td>3 (10.00)</td>
<td>55 (35.48)</td>
<td>137 (86.71)</td>
<td>34 (23.13)</td>
<td>381 (12.45)</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td></td>
<td>0</td>
<td>10 (0.93)</td>
<td>6 (1.33)</td>
<td>5 (0.94)</td>
<td>35 (22.58)</td>
<td>0</td>
<td>11 (7.48)</td>
<td>62 (2.03)</td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td></td>
<td>0</td>
<td>34 (3.15)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (1.29)</td>
<td>0</td>
<td>3 (2.04)</td>
<td>39 (1.27)</td>
</tr>
<tr>
<td>COVID-19 confirmed</td>
<td></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

* Of all patients with MS from centers in Beijing, 154 patients were from Beijing Tiantan Hospital, 206 were from the General Hospital of Chinese People’s Liberation Army, and 436 from Peking Union Medical College Hospital.
* For patients receiving interferon beta treatment in Hong Kong, 25 received Rebif, 5 received Avonex, and 4 received Betaferon. In other centers, patients received Betaferon treatment.
* Of all patients with NMOSD from centers in Beijing, 280 patients were from Beijing Tiantan Hospital, 101 were from the General Hospital of Chinese People’s Liberation Army, and 698 from Peking Union Medical College Hospital.
* Methylprednisolone was used as monotherapy.
* A proportion of patients who received treatment with immunosuppressants used concomitant methylprednisolone.
From the start of the SARS-CoV-2 epidemic in December 2019 and during its progression in China, neuroimmunologists have paid special attention to their patients with MS and NMOSD receiving DMDs who are at increased risk for infection. Meticulous preventive protocols have been adopted, which have undoubtedly minimized the exposure of these at-risk patients, and thereby have contributed to the absence or low rates of SARS-CoV-2 infection in our patients. These measures include but are not limited to the following: scaling up viral test capacities and swift isolation of infected patients, online patient consultations to reduce visits to hospitals, and coordinating patients with local care givers to perform infusions and routine monitoring. Moreover, new patients or those with a suspected new MS or NMOSD attack were segregated in special hospital units with single rooms, which is not a common practice in Chinese inpatient facilities. Portions of the Department of Neurology have further been reconfigured to accommodate patients with suspected infected. Visits from friends and relatives have been strictly controlled.

This study has several limitations. Self-reporting and questionnaires may have missed some patients, especially those who had minor symptoms. In rare cases, patients refused to disclose this information to avoid mandatory quarantine in designated facilities. One aspect of the DMDs available for patients from mainland China and durations on DMDs differs from those in other countries. Specifically, natalizumab, cladribine, and alemtuzumab are not available to the patients from mainland China. Nevertheless, the collection of DMDs used by patients from Hong Kong, Korea, Japan, and Singapore are similar to those used in the United States and EU, implying the generality of our conclusions.

Despite these limitations, our data originated from a large number of patients that include individuals from the hardest hit city of Wuhan and its surrounding regions, arguing against a significantly increased risk of COVID-19 infection and disease in patients with MS and NMOSD treated with DMDs. However, a variety of stringent measures that have been taken to protect these patients must have contributed to relative low risk of COVID-19 infection in our cohort. Because COVID-19 has already infected 3,387 medical professionals and has caused 28 deaths among them in China, extraordinary steps in managing neurologic patients to protect both patients and medical professionals from COVID-19 infection are critically important. Because COVID-19 is becoming a serious global health concern and its spread is still intensifying in many parts of the world, a full-scale preparedness plan, with unconditional support for manpower and resources from federal and local governments, is required to better manage neurologic patients during the pandemic.
Dedication

This article is dedicated to our colleagues Bin Zhao, Guangxun Yan, Yuanyuang Qu, Shasha Han, Mengxi Li, Lianghui Yang, Lei Su, Jing Xu, Mengya Xing, Zhe Zhang, Jinmei Wang, Wei-Na Jin from the Departments of Neurology, Tianjin Medical University General Hospital and Beijing Tiantan Hospital, and to those medical professionals across China, who went to Wuhan, and Departments of Infectious Disease caring for patients with COVID-19.

Acknowledgment
The authors thank the following neurologist colleagues for sharing information on the risk of COVID-19 infections in their clinics: Kazuo Fujihara, MD (Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Japan); Ho Jin Kim, MD, PhD (Division of Clinical Research, Research Institute & Hospital of National Cancer Center, Korea); Kevin Tan, BM BS, MRCP (UK) (Department of Neurology, National Neuroscience Institute, Singapore); Weibin Liu, MD (The First Affiliated Hospital of Sun Yat-sen University, Guangzhou); Ying Fu, MD (The First Affiliated Hospital of Fujian Medical University, Fuzhou); Xiaokun Qi, MD (The Navy General Hospital, Beijing); Guanzhi Liu, MD (Beijing Anzhen Hospital, Capital Medical University, Beijing); Zeyu Li, MD (The Affiliated Hospital of Inner Mongolia Medical University, Hohhot); Jiawei Wang, MD (Beijing Tongren Hospital, Capital Medical University, Beijing); Lihua Wang, MD (The 2nd Affiliated Hospital of Harbin Medical University, Harbin); Tao Jin, MD (First Hospital of Jilin University, Changchun); Manxia Wang, MD (The Second Hospital of Lanzhou University, Lanzhou); Xiangjun Chen, MD (Huashan Hospital Fudan University, Shanghai). The authors also thank D.-C. Tian, K.-B. Shi, and members of Jing-Jin Neuroimmunology team for extensive support; Drs. Luc Van Kear and Samuel X. Shi for English editing.

Study funding
This study was supported by the Advanced Innovation Center for Human Brain Protection (Neuroimmune 01), and the National Science Foundation of China (91642205, 81830038, and 81601019).

Disclosure
The authors report no disclosures relevant to the manuscript. None of the funding organizations were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. Go to Neurology.org/NN for full disclosures.

Publication history
Received by Neurology: Neuroimmunology & Neuroinflammation April 20, 2020. Accepted in final form April 27, 2020.
Appendix Authors

Name | Location | Contribution
--- | --- | ---
Moli Fan, MD, PhD | Department of Neurology, Tianjin Medical University General Hospital, China | Data collection, statistical analysis, data interpretation, and administrative, technical, or material support
Wei Qiu, MD, PhD | Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China | Data collection, statistical analysis, and data interpretation
Bitao Bu, MD, PhD | Department of Neurology, Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China | Data collection, statistical analysis, and data interpretation
Yan Xu, MD, PhD | Department of Neurology, Peking Union Medical College Hospital, Beijing, China | Data collection, statistical analysis, and data interpretation
Huan Zhang, MD, PhD | Department of Neurology, Xiangya Hospital of Central South University, Changsha, China. | Data collection, statistical analysis, and data interpretation
Dehui Huang, MD | Department of Neurology, General Hospital of Chinese People's Liberation Army, Beijing, China | Data collection, statistical analysis, and data interpretation
Alexander Y. Lau, MD | Division of Neurology, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, China | Data collection, statistical analysis, and data interpretation
Jun Guo, MD, PhD | Department of Neurology, Tangdu Hospital, Air Force Military Medical University, Xi’an, China | Data collection, statistical analysis, and data interpretation
Mei-Ni Zhang, MD | Department of Neurology, The First Affiliated Hospital of Shanxi Medical University, Taiyuan, China | Data collection, statistical analysis, and data interpretation
Xinghu Zhang, MD | China National Clinical Research Center for Neurological Diseases, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China | Data collection, statistical analysis, and data interpretation
Chun-Sheng Yang, MD, PhD | Department of Neurology, Tianjin Medical University General Hospital, China | Data collection, statistical analysis, and data interpretation and administrative, technical, or material support

Appendix (continued)

Name | Location | Contribution
--- | --- | ---
Jingshan Chen, MD | Department of Neurology, Tianjin Medical University General Hospital, China | Data collection, statistical analysis, data interpretation and drafting of the manuscript, and administrative, technical, or material support
Pei Zheng, MD | Department of Neurology, Tianjin Medical University General Hospital, China | Data collection, statistical analysis, data interpretation and drafting of the manuscript, and administrative, technical, or material support
Qiang Liu, MD, PhD | Department of Neurology, Tianjin Medical University General Hospital, China | Data collection, statistical analysis, data interpretation and drafting of the manuscript
Chao Zhang, MD, PhD | Department of Neurology, Tianjin Medical University General Hospital, China | Data collection, statistical analysis, data interpretation, drafting of the manuscript, and administrative, technical, or material support
Fu-Dong Shi, MD, PhD | Department of Neurology, Tianjin Medical University General Hospital, China | Concept and design, obtained funding, data collection, statistical analysis, data interpretation, drafting of the manuscript, supervision of this study, and administrative, technical, or material support

References

Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders
Moli Fan, Wei Qiu, Bitao Bu, et al.
*Neurol Neuroimmunol Neuroinflamm* 2020;7;
DOI 10.1212/NXI.0000000000000787

This information is current as of June 4, 2020